• ACE2 Signaling in Sepsis-Related Heart Injury

  2026-11-06

  A mouse study examined whether ACE2 perturbation changes sepsis-induced cardiomyopathy and whether MasR-Sirt1-linked mitochondrial biogenesis helps explain the observed pattern. The findings support a mechanistic association in this model while leaving questions about translation and pharmacological specificity open.

• What Multiplex CRISPR Evidence Really Shows

  2026-11-06

  Multiplex CRISPR–Cas can reveal gene interactions and generate complex genomic changes, but the same breadth increases uncertainty from collateral DNA damage, off-target activity, delivery constraints, and repair-dependent outcomes.

• NHE1, Octanal and Atherosclerotic Inflammation

  2026-11-05

  A complementary mouse and macrophage study supports a model in which octanal/Olfr2 signaling is associated with NHE1 activation, calcium- and oxidative-stress responses, and inflammatory foam-cell phenotypes. Genetic and pharmacologic perturbations strengthen the pathway interpretation, while the ordering of calcium, ROS, and NHE1 events remains unresolved and the evidence remains preclinical.

• Diminazene Aceturate and Septic Heart Mechanisms

  2026-11-05

  A mouse study used Diminazene Aceturate as a pharmacological probe of ACE2-linked protection in sepsis-induced cardiomyopathy. Its findings connect ACE2, MasR–Sirt1 signaling, mitochondrial biology, inflammation, oxidative stress, and cardiac dysfunction, while leaving target specificity and clinical applicability unresolved.

• When Context Changes a Biological Result

  2026-11-04

  The same compound can represent a trypanocidal research tool in one setting and a pharmacological probe of ACE2 signaling in another. A mouse sepsis study illustrates how model choice, comparator design, and readout determine what a result can—and cannot—mean.

• ACE2, Mitochondria and Septic Cardiomyopathy

  2026-11-04

  A mouse study linked pharmacological ACE2 activation by Diminazene Aceturate with improved cardiac and survival-associated outcomes during experimental sepsis. Its findings support a MasR–Sirt1 mitochondrial-biogenesis model, while pharmacological specificity, model transferability and limited quantitative reporting constrain interpretation.

• Diminazene Aceturate and ACE2 in Septic Heart Injury

  2026-11-03

  A mouse study used Diminazene Aceturate as a pharmacological probe of ACE2 signaling in sepsis-induced cardiomyopathy. The reported protection was associated with MasR–Sirt1 signaling and mitochondrial-biogenesis readouts, while the pharmacological design leaves target specificity, causal ordering, and clinical relevance unresolved.

• Diminazene Aceturate and ACE2 Mechanism

  2026-11-03

  A mouse study links pharmacological ACE2 activation with MasR–Sirt1 signaling, mitochondrial biogenesis and improved cardiac phenotypes during sepsis. The findings are mechanistically informative but remain limited by pharmacological specificity, model dependence and the absence of direct evidence for clinical translation.

• ACE2–MasR–Sirt1 in Septic Cardiomyopathy

  2026-11-02

  A mouse study used Diminazene Aceturate as a pharmacological probe of ACE2 signaling and linked ACE2 activity with MasR–Sirt1-associated mitochondrial biogenesis, cardiac dysfunction, inflammation, oxidative stress and apoptosis during experimental sepsis. The findings support a mechanistic hypothesis, but pharmacological specificity, model scope and clinical translation remain unresolved.

• Diminazene Aceturate in Septic Cardiomyopathy

  2026-11-02

  A literature-focused analysis of how Diminazene Aceturate functioned as a pharmacological ACE2 probe in a mouse model of sepsis-induced cardiomyopathy, what the MasR–Sirt1 findings establish, and where interpretation remains limited.

• ACE2, Mitochondria, and Septic Heart Injury

  2026-11-01

  A literature-focused analysis of how diminazene aceturate was used as a pharmacological ACE2 probe in a mouse model of sepsis-induced cardiomyopathy, what the MasR–Sirt1 findings establish, and where the evidence remains limited.

• When Context Changes a Research Result

  2026-10-31

  Diminazene Aceturate illustrates why a result cannot be separated from its model, comparator, mechanism and readout. Its trypanocidal research context differs fundamentally from its use as a pharmacological ACE2 probe in a mouse model of sepsis-induced cardiomyopathy.

• Diminazene Aceturate and Septic Cardiomyopathy

  2026-10-30

  A mouse study links pharmacological ACE2 perturbation to cardiac dysfunction, inflammation, oxidative stress, apoptosis, and MasR-Sirt1-associated mitochondrial biogenesis, while leaving target specificity and translational relevance unresolved.

• Diminazene Aceturate and Sepsis Cardiac Injury

  2026-10-30

  A literature-focused analysis of a murine study connecting pharmacological ACE2 activation by Diminazene Aceturate with improved cardiac outcomes during sepsis. The findings support an ACE2–MasR–Sirt1 mitochondrial-biogenesis model, while remaining limited by pharmacological specificity, model transferability and the absence of numerical effect sizes in the accessible abstract-level record.

• Diminazene Aceturate and Septic Cardiomyopathy

  2026-10-29

  A mouse study links pharmacological ACE2 modulation by Diminazene Aceturate with MasR–Sirt1-associated mitochondrial biogenesis and improved features of sepsis-induced cardiomyopathy. The findings support a mechanistic hypothesis, but they do not establish pathway specificity, human efficacy, or a therapeutic role beyond the reported experimental context.

8520 records 1/568 page Next 12345 下5页 Last page